글로벌 마이크로버블 대조 매체 시장 – 2029년까지의 산업 동향 및 예측

 마이크로버블 대조 매체 시장 분석 및 규모

초음파 영상에서 미세기포 조영제를 사용하여 일반적인 조직 구분 및 관류를 하는 것이 인기를 얻고 있습니다. 조영제인 미세기포는 복용량이 낮고 검출 감도가 뛰어납니다. 미세기포 표면에 리간드를 타겟팅하면 혈관 내피 세포에 수용체 분자 수준이 증가한 관심 영역에 이러한 입자를 선택적으로 축적할 수 있습니다. 이러한 제품은 수술 전 검사와 중재적 시술에서 치료가 필요한지 여부를 판단하는 데 도움이 되며, 이는 미세기포 조영제 시장 성장에 도움이 될 것으로 기대됩니다.

Data Bridge Market Research는 2022년부터 2029년까지의 예측 기간 동안 건강한 CAGR로 예상되는 미세기포 대조 매체 시장을 분석합니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

마이크로버블 대조 매체 시장 범위 및 세분화  

Market Definition

Contrast media, also known as contrast agents, is a substance that is usually transparent to X-rays and is used in medical imaging to speed up the contrast of fluids or structures. Microbubbles are used as a blood pool agent for contrast ultrasound imaging in cardiology and radiology. They are widely used in gene therapy, stem cell delivery, drug delivery, molecular imaging, and other applications. Microbubbles can also be used in conjunction with ligand molecules that target molecular markers of disease. The main purpose of microbubble-based ultrasound contrast agents is to monitor the biomarker condition of vascular endothelium, image inflammation, and visualise tumour vasculature, among other things.

Global Microbubble Contrast Media Market Dynamics

Drivers

• Increasing image-guided surgeries

Image-guided surgeries (IGS) are gaining popularity. These procedures can be used to diagnose and treat a variety of conditions. The growing need and demand for imaging refinement during surgeries necessitates novel methods of data acquisition, processing, and display, as well as a thorough understanding of the imaging process and its applications in therapy. This need is very well served by image-guided procedures, which has resulted in increased demand for image-guided procedures for diagnostics and treatment, and thus has served as a market growth factor.

• Increasing prevalence of complex comorbidities

The increasing prevalence of complex comorbidities and chronic diseases has increased diagnostic imaging tests such as ultrasound, X-rays, and advanced imaging technology such as MRI and CT scans. For instance, GE Healthcare received FDA approval for Clariscan, a contrast agent used in macrocyclic MRI in November 2019. These products aid in the identification of the need for perioperative scans prior to surgeries and treatment in interventional procedures, which is expected to drive market growth.

Opportunities

• Rise in the prevalence of chronic conditions

The occurrence of chronic conditions with multiple comorbidities is higher in elder people. According to the National Council on Aging, nearly 80% of people aged 65 and older have at least one chronic condition, with nearly 70% of Medicare beneficiaries having more than two chronic conditions, and nearly 77.0 million people in the United States are expected to be 65 and older by 2034.

Furthermore, according to an American Heart Association report, the incidence of heart failure is increasing in the United States, and it is one of the leading causes of death in the country. In the United States in 2020, approximately 659,000 people died as a result of cardiovascular diseases. The number of people with heart disease is expected to rise by 46% by 2030.

• Launch of new products

The launch of digital tools to help with contrast agent injection management is projected to fuel market expansion. For instance, in 2018, Guerbet introduced Contrast&Care 2.0, a digital system that links all CT, Cath lab, and MRI injectors and has smart reader & connectivity features, allowing users to scan and read data on both their smartphones and laptops.

Restraints/Challenges

• High cost of microbubble contrast media

High cost of microbubble contrast media and the low adoption rate in emerging and underdeveloped countries will obstruct the market's growth rate. Imaging the kidney with microbubble contrast agents because of the poor contrast of B-mode imaging for parenchymal disease and the limited sensitivity of colour doppler for the detection of intracortical capillaries and deep pedicular vessels.

This microbubble contrast media market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the microbubble contrast media market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Microbubble Contrast Media Market

The COVID-19 epidemic negatively impacted the microbubble contrast media market, resulting in a drop in patient visits to hospitals. The introduction of accurate and efficient digital methods for managing contrast agent injection is predicted to drive market expansion. Numerous research has shown that COVID has a devastating impact on health, including heart attacks and strokes, this may drive future market expansion. The pandemic has put tremendous strain on the healthcare systems. To conserve healthcare resources for COVID-19 patients and stem the spread of the disease, healthcare institutions and providers were directed to stop performing medical examinations and elective surgical procedures. As a result the patients concentrating on COVID-19 in the early months of the pandemic, the diagnosis of cardiac diseases decreased by nearly two-thirds globally. Similar declines in colon, breast, prostate, and lung screenings—75%, 85%, 75%, 74%, and 56%, respectively—show a decline in revenue for 2020.

Recent developments

• In February 2022, Lopamidal by Beijing Beilu Pharmaceuticals passed the generic drug Consistency Evaluation. The evaluation aids in comparing the quality and efficacy of generic drugs to the brand version of the drug.
• In July 2020, Bayer and Siemens Healthineers presented a new Imaging System Interface (ISI) for magnetic resonance imaging. The Interface combines the Bayer MRXperion MR Injection System and the Siemens Healthineers MR scanner to overcome the limitations of the traditional method.

Global Microbubble Contrast Media Market Scope

The microbubble contrast media market is segmented on the basis of therapeutic area, application, route of administration, form and procedures. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapeutic Area

• Cardiovascular Diseases
• Renal and Associated Diseases
• Others

 Application

• Molecular Imaging
• Gene Therapy
• Drug Delivery
• Stem Cells Delivery

 Route of Administration

• Rectal
• Oral
• Injectable

 Form

• Tablet
• Powder
• Liquid
• Paste

 Procedures

• X-ray/Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)

Microbubble Contrast Media Market Regional Analysis/Insights

The microbubble contrast media market is analyzed and market size insights and trends are provided by country, therapeutic area, application, route of administration, form and procedures as referenced above.

The countries covered in the microbubble contrast media market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the microbubble contrast media market due to an increase in the availability of advanced technologies, the presence of well-established healthcare facilities, and the demand for diagnostic procedures in this region. 

Asia-Pacific is expected to dominate at the highest growth rate in the forecast period of 2022 to 2029 due to the rise in the research and development investment in the contrast agents in this region and the prevalence of chronic disease.

보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 트렌드 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 마이크로버블 대조 매체 시장 점유율 분석

마이크로버블 콘트라스트 미디어 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 포함됩니다. 위에 제공된 데이터 포인트는 마이크로버블 콘트라스트 미디어 시장과 관련된 회사의 초점에만 관련이 있습니다.

미세기포 대조 매체 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 란테우스(미국)
• 브라코 이미징 SpA(이탈리아)
• 제너럴 일렉트릭(미국)
• 다이이치 산쿄 주식회사(일본)
• nanoPET Pharma GmbH(독일)
• Trust Bio-sonics (대만)
• FUJIFILM VisualSonics Inc. (캐나다)
• Trivitron Healthcare(인도)
• 지멘스(독일)

SKU-44769